BioCentury on BioBusiness,
Emerging Company Profile
Avilex's dimeric inhibitor shows greater potency for pain target PSD95
Related tables, figures and sidebars
Avilex: One-two pain punch
Monday, April 29, 2013
Pharma ApS may have found a way to block activation of the NMDA
receptor pathway to treat chronic pain and ischemic stroke. Rather than
directly hitting the receptor itself, the approach targets a downstream player
in the pathway and thus could avoid many of the side effects of NMDA receptor
The NMDA receptor is expressed
on the surface of many CNS cell types and is known to mediate production of
excess nitric oxide (NO), which leads to neuronal excitotoxicity and the
development of neuropathic and chronic pain as well as nerve damage following
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]